France's Sanofi to buy Synthorx for $2.5 billion

赛诺菲斥资25亿美元收购Synthorx

2019-12-09 15:37:16 YAHOO!FINANCE

本文共377个字,阅读需1分钟

PARIS - France's Sanofi said on Monday it had agreed to buy Synthorx in a cash deal worth around $2.5 billion as it seeks to beef up its immuno-oncology pipeline. Under the terms of the merger agreement, Sanofi has offered to buy all of the outstanding shares of Synthorx common stock for $68 per share in cash. The $68 per share acquisition price represents a 172% premium to Synthorx’s closing price on Dec. 6, 2019. "This acquisition ...is aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations," Sanofi CEO Paul Hudson said in a statement. Sanofi is conducting a broad strategy review under new chief executive Paul Hudson, who will give some initial pointers on which businesses he wants to focus on at an investor day on Dec. 10. (Reporting by Dominique Vidalon; Editing by Kim Coghill)
法国的赛诺菲(Sanofi)。PA >周一说,它已同意以25亿美元的现金收购 Synthorx ,以加强其免疫肿瘤治疗渠道。 根据合并协议的条款,赛诺菲(Sanofi)提出以每股68美元的现金购买 Synthorx 普通股的全部流通股。 每股68美元的收购价格比 Synthorx 2019年12月6日的收盘价溢价172%。 "本次收购。。。赛诺菲(Sanofi)首席执行官保罗·哈德森在一份声明中说:“这与我们的目标一致,即利用可能改变临床实践的药物和新的药物组合来建立我们的肿瘤特许经营。” 赛诺菲(Sanofi)正在新任首席执行官保罗•哈德森( Paul Hudson )的领导下进行广泛的战略评估,他将在12月10日的投资者日给出一些他希望关注的企业的初步指标。 ( Dominique Vidalon 的报道; Kim Coghill 的编辑)

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文